Search PubMed⌕ Search

Biomedical subjects

C Tsoukas

Publications and source records attributed to C Tsoukas.

56 records · Page 4Linked to original sources
PubMedDate not supplied

Natural history of the AIDS related complex in hemophilia--relationships to Epstein Barr virus.

Several cases of hemophiliacs with AIDS have been reported. These case reports have prompted studies of asymptomatic healthy hemophiliacs. During these studies, we found four hemophiliacs who presented a distinct clinical syndrome identical to the lymphadenopathy syndrome in homosexuals which has been considered a prodrome to AIDS. Our results demonstrated that the AIDS related complex in hemophiliacs is characterized by recurrent herpes viral infections. Furthermore, the clinical and laboratory data in these patients suggest that this syndrome does not inexorably lead to AIDS, and may be a manifestation of a group of disorders in which AIDS represents one end of the spectrum.

Acquired Immunodeficiency Syndrome↗
PubMedDate not supplied

Study protocol for the evaluation of the potential for durable viral suppression after quadruple HAART with or without HIV vaccination: the QUEST study.

PURPOSE: By protecting and stimulating HIV-specific CD4 cell responses, treatment of primary HIV infection (PHI) with potent quadruple HAART could lead to prolonged suppression of HIV replication after cessation of antiretroviral therapy. The QUEST trial investigates this hypothesis and aims to determine whether addition of a therapeutic vaccine to HAART increases the likelihood of prolonged viral suppression compared to HAART alone. METHOD: 148 patients with PHI were recruited. Participants were treated with open-label HAART for at least 76 weeks. Participants with sustained viremia <50 copies/mL were randomized to one of three 5-month, double-blinded study treatment groups: HAART alone, HAART + ALVAC-HIV (vCP1452), or HAART + ALVAC-HIV (vCP1452) + Remune. After a further month of HAART alone, all treatment was stopped where plasma HIV-1 RNA remained at <50 copies/mL. Intensive virologic and immunologic monitoring during a 24-week observation period followed treatment interruption. Patients who met treatment reintroduction criteria were offered HAART rescue.

AIDS Vaccines↗